FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Petr Novák, Michal Novák|Alzheimer s Research & Therapy|2018

Cited by 141